YY1 and cancer: Based on these results, we propose that targeting the YY1/GHITM/Notch1 axis could decrease the malignant behaviour of KIRC cells and potentiate antitumour efficacy of cancer therapy, which provides a promising and novel therapeutic strategy for KIRC patients.